Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Sep 8:3:21.
doi: 10.1186/1471-2474-3-21.

Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome

J H Raphael  1 , J L Southall, G J Treharne, G D Kitas
Affiliations

Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome

J H Raphael et al. BMC Musculoskelet Disord. .

Abstract

Background: To investigate the effects of intravenous lignocaine infusions (IV lignocaine) in fibromyalgia.

Methods: Prospective study of the adverse effects of IV lignocaine in 106 patients with fibromyalgia; retrospective questionnaire study of the efficacy of IV lignocaine in 50 patients with fibromyalgia.

Results: Prospective study: Two major (pulmonary oedema and supraventricular tachycardia) and 42 minor side-effects were reported. None had long-term sequelae. The commonest was hypotension (17 cases). Retrospective study: Pain and a range of psychosocial measures (on single 11-point scales) improved significantly after treatment. There was no effect of the treatment on work status. The average duration of pain relief after the 6-day course of treatment was 11.5 +/- 6.5 weeks.

Conclusions: Intravenous lignocaine appears to be both safe and of benefit in improving pain and quality of life for patients with fibromyalgia. This needs to be confirmed in prospective randomised controlled trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pain severity pre-and post-lignocaine
Figure 2
Figure 2
Duration of pain relief with IV lignocaine
See this image and copyright information in PMC

References

    1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72. - PubMed
    1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–27. - PubMed
    1. Bennett RM. Fibromyalgia and the disability dilemma: A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum. 1996;39:1627–34. - PubMed
    1. Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome: An outcome study. Br J Rheumatol. 1993;32:139–42. - PubMed
    1. Goldenberg DC, Felson DT, Dinerman H. A randomized controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29:1371–7. - PubMed

LinkOut - more resources